• Alias: AP 12009
    • An antisense oligonucleotides that binds to TGF-β2 mRNA causing the inhibition of protein translation, thereby decreasing TGF-β2 protein levels
    • No active clinical trials in the United States
    • Recommended phase 2 dose: 140 mg/m2/day IV 4 days on, 10 days off; 10 to 80 μM intratumoral infusion daily for 7 days on, 7 days off (gliomas)
    • Half-life: 1.12 to 2.08 hours
    • Common side effects: Thrombocytopenia
    (Bogdahn et al., 2011; Oettle et al., 2012)
    Other topics in Targeted and Immunotherapy Agents